Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 38497

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

SJB2-043 analog is an inhibitor of OTUB1 and ubiquitin-specific protease 8 (USP8; IC50s = 0.17 and 0.28 nM, respectively) and a derivative of the USP1/UAF1 complex and SARS-CoV-2 PLPro inhibitor SJB2-043 (Item No. 36605).1 It is selective for OTUB1 and USP8 over USP1, USP2, USP7, USP36, and ataxin-3 (IC50s = 1,370, 3,800, >10,000, 8,400, and >10,000 nM, respectively). SJB2-043 analog reduces viability in H1975, EBC-1, NCI H1703, H23, and A549 non-small cell lung cancer (NSCLC) cells (IC50s = 118, 172, 145, 431, and 1,004 nM, respectively). In vivo, SJB2-043 analog (5 mg/kg twice daily) decreases tumor volume in an H1975 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of potent OTUB1/USP8 dual inhibitors targeting proteostasis in non-